Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients

被引:82
作者
Fujiki, Youhei [1 ]
Kotani, Takuya [1 ]
Isoda, Kentaro [2 ]
Ishida, Takaaki [1 ]
Shoda, Takeshi [2 ]
Yoshida, Shuzo [1 ]
Takeuchi, Tohru [1 ]
Makino, Shigeki [1 ]
机构
[1] Osaka Med Coll, Dept Internal Med 4, Daigaku Machi 2-7, Takatsuki, Osaka 5698686, Japan
[2] Yodogawa Christians Hosp, Dept Rheumatol, Internal Med, Osaka, Japan
关键词
Dermatomyositis; interstitial pneumonia; prognosis; LUNG-DISEASE; AMYOPATHIC DERMATOMYOSITIS; POLYMYOSITIS; POLYMYOSITIS/DERMATOMYOSITIS; COMPLICATION; MYOSITIS; HRCT;
D O I
10.1080/14397595.2017.1318468
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We retrospectively investigated clinical prognostic factors for interstitial pneumonia (IP) in anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive dermatomyositis (DM) patients. Methods: Subjects comprised 18 patients with anti-MDA5 Ab-positive DM-IP (9 survivors; 9 deaths). Results: Initial serum albumin levels, ferritin levels, and ground-glass opacity (GGO) scores in the right middle lobes were significantly higher in the death group than in the survivor group (p = .033, .013, and .005, respectively). Initial alveolar-arterial oxygen gradient (P[A-a]O-2) was also higher in the death group than in the survivor group (p = .064). Initial serum ferritin, P[A-a]O-2, and right middle lobe GGO score were found to significantly relate to death. Survival rates after 24 weeks were significantly lower among patients with an initial ferritin level of >= 450 ng/mL (25%), P[A-a]O-2 of >= 30 mmHg (31%), and a right middle lobe GGO score of >= 2 (11%) than each of the others (p = .006, .020, and .002, respectively). Conclusions: An initial serum ferritin level of >= 450 ng/mL, P[A-a]O-2 of >= 30 mmHg, and right middle lobe GGO score of >= 2 (GGO >= 5% of the lobe) were identified as poor prognostic factors for anti-MDA5 Ab-positive DM-IP patients.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 50 条
[41]   Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis [J].
Gui, Xianhua ;
Ma, Miao ;
Ding, Jingjing ;
Shi, ShenYun ;
Xin, Xiaoyan ;
Qiu, Xiaohua ;
Zhang, Yingwei ;
Qiu, Yuying ;
Cao, Min ;
Huang, Mei ;
Cao, Mengshu ;
Dai, Jinghong ;
Cai, Hourong ;
Xiao, Yonglong .
RHEUMATOLOGY, 2021, 60 (08) :3913-3922
[42]   The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients [J].
Ono, Nobuyuki ;
Kai, Keita ;
Maruyama, Akihito ;
Sakai, Mariko ;
Sadanaga, Yuri ;
Koarada, Shuichi ;
Inoue, Takuya ;
Tada, Yoshifumi .
RHEUMATOLOGY, 2019, 58 (05) :786-791
[43]   Correlation between B-cell epitope profile and clinical features of anti-MDA5 antibody-positive dermatomyositis [J].
Yamaguchi, Koichi ;
Poland, Paul ;
Bijoy George, Tissa ;
Saygin, Didem ;
Moghadam-Kia, Siamak ;
Aggarwal, Rohit ;
Oddis, Chester V. ;
Zhu, Lei ;
Ascherman, Dana P. .
RHEUMATOLOGY, 2023, 63 (07) :2016-2023
[44]   Clinical Characteristics of Lipid Metabolism in Untreated Patients with Anti-MDA5 Antibody-Positive [J].
Huang, Wenhan ;
Ren, Feifeng ;
Luo, Lei ;
Zhou, Jun ;
Huang, Dongmei ;
Tang, Lin .
INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 :2507-2512
[45]   Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis [J].
Wanlong Wu ;
Li Guo ;
Yakai Fu ;
Kaiwen Wang ;
Danting Zhang ;
Wenwen Xu ;
Zhiwei Chen ;
Shuang Ye .
Clinical Reviews in Allergy & Immunology, 2021, 60 :293-304
[46]   Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis [J].
Ho So ;
Victor Tak Lung Wong ;
Virginia Weng Nga Lao ;
Hin Ting Pang ;
Ronald Man Lung Yip .
Clinical Rheumatology, 2018, 37 :1983-1989
[47]   Monoclonal antibodies from B cells of patients with anti-MDA5 antibody-positive dermatomyositis directly stimulate interferon gamma production [J].
Coutant, Frederic ;
Bachet, Rafael ;
Pin, Jean-Jacques ;
Alonzo, Marina ;
Miossec, Pierre .
JOURNAL OF AUTOIMMUNITY, 2022, 130
[48]   Plasma exchange for anti-MDA5 antibody-positive dermatomyositis-associated rapidly progressive interstitial lung disease: A case report and literature review [J].
Lu, Ci ;
Xu, Cheng ;
Zhu, Xiaoying ;
Han, Yongmei .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2023, 51 (09)
[49]   Tension Pneumomediastinum in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease: A Case Report and Literature Review [J].
Okabayashi, Hiroko ;
Nakashima, Seiya ;
Fujino, Kosuke ;
Imai, Miyu ;
Hamada, Shohei ;
Masunaga, Aiko ;
Ichiyasu, Hidenori ;
Suzuki, Makoto ;
Sakagami, Takuro .
INTERNAL MEDICINE, 2024, 63 (23) :3221-3226
[50]   Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis [J].
Ida, Tomoaki ;
Furuta, Shunsuke ;
Takayama, Asuka ;
Tamura, Jun ;
Hayashi, Yuki ;
Abe, Kazuya ;
Kurihara, Syunjiro ;
Ishikawa, Junichi ;
Iwamoto, Taro ;
Ikeda, Kei ;
Suzuki, Kotaro ;
Nakajima, Hiroshi .
RMD OPEN, 2023, 9 (01)